The present biespec u00edficos Antibodies are useful for treating autoimmune diseases, including systemic lupus erythematosus, lupus nephritis and primary Sjogren's Syndrome. Claim 1: a biespec u00ed ufb01co Antibody polypeptide Chains which comprises two first and Two second polypeptide Chains where each,.) the first polypeptide Chain comprising a single Chain variable Fragment (scFv) and a heavy chain of IgG MAB (HC, HC) that has a variable region of the heavy chain (hcvr1) comprising regions of heavy chain (hcdr) 1 - 3 where the amino acid sequence of SEQ is the hcdr1 I D no. 9, the amino acid sequence of hcdr2 is SEQ ID no 10The amino acid sequence of SEQ ID no. hcdr3 is 11, and the scFv has a variable region of the heavy chain (hcvr2) and a variable region of light chain (lcvr2), hcvr2 comprising hcdrs 4 - 6 and lcvr2 that comprencle lcdrs 4 - 6, where the amino acid sequence of hcdr4 is the SEQ ID no. 12, the amino acid sequence of hcdr5 is SEQ ID no. 13The amino acid sequence of hcdr6 is SEQ ID no. 14, lcdr4 is the amino acid sequence of SEQ ID no. 18, the amino acid sequence of SEQ ID no. lcdr5 is 19, and the amino acid sequence of lcdr6 is SEQ ID no. 20； and B.) the second polypeptide comprises a light chain (LC) MAB comprising light chain CDR (LCdr) 1 - 3, where the amino acid sequence of lcdr1 is SEQ ID no. 15, the amino acid sequence of SEQ ID no. lcdr2 is 16, the amino acid sequence of lcdr3 is SEQ ID no. 17,Where each scFv binds independently to the HC through Linker polypeptide (L1) covalently joined to the n-terminus of HC and the c-terminal lcvr2, and lcvr2 hcvr2 scFv binds to the same by means of a Second polypeptide Linker (L2) of the Covalent mode e Lcvr2 Xtremo c-terminal and the n-terminal end of hcvr2.Claim 5: a DNA Molecule comprising a polynucleotide Sequence encoding a polypeptide Chain which has the amino acid sequence of SEQ ID no. 1.Claim 8: a Mammalian Cell comprising the DNA Molecule of Claim 5 and the DNA Molecule of claim 6, this cel
